Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

There is decreased risk for hospitalization in patients with heart failure who receive a high-dose inactivated influenza vaccine.

Australian biotech CSL yesterday has delayed its planned vaccine division spin-off and cut earnings forecasts due to a bigger-than-expected decline in US flu vaccination rates, sending its shares down ...

CSL ( ASX: CSL) cut its fiscal 2026 guidance for revenue and net profit after tax before amortization growth to 3% and 6% at the midpoint, respectively, from 5% and 9%. This was driven by declines in ...

GSK Plc raised its profit and sales forecasts for the year, aided by demand for its HIV and immunology medicines, in Emma ...

The "United States Adult Vaccine Market Report by Disease wise - Adult Vaccines Market, Disease wise - Numbers of Vaccinated Adults, States and Company Analysis, 2025-2033" report has been added to ...

Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the ...